Loading
A phase 2 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Fudan University, now recruiting.
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT06281405 by Fudan University, with a registry enrolment figure of 192 participants, started 2024-03-28 and due to reach its primary completion in 2026-06-30. Interventions recorded: PD-1 inhibitor; Capecitabine; Short-course radiotherapy; Oxaliplatin. Conditions listed: Locally Advanced Rectal Cancer; Neoadjuvant Therapy. Primary outcome: Complete response (CR) rate. Sites: China. No results are recorded here; the registry entry is the source.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.